亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Extracellular matrices and methods for treating peripheral artery disease (PAD)

詳細技術說明
Researchers at the University of California, San Diego have developed tissue specific decellularized matrices for treating peripheral artery disease, critical limb ischemia, and have potential for skeletal muscle tissue engineering. Mammalian extracellular matrix provides scaffolds for cell growth, recruitment and replacement as well as a biocompatible material that can be used to deliver drugs to specific tissues (e.g. skeletal myoblasts, stem cells, and other cell types relevant to skeletal muscle repair).
*Abstract

Despite recent advances in tissue engineering and regenerative medicine, ischemia related to cardiovascular disease results in the death of more than 100,000 amputations per year from peripheral artery disease (PAD) in the US alone.  Very few biomaterials have been examined and of those examined (e.g. fibrin, collagen, alginate, and Matrigel). None of these provide all the native components of the skeletal muscle extracellular matrix. Most are limited to improving growth factor and cell delivery. Currently no material meets all of the properties of an ideal scaffold, namely enhanced neovascularization to reduce the ischemic environment, better cell adhesion, survival, and maturation of endogenous or exogenously added cells. There is a need to develop improved compositions for minimally invasive tissue-engineered therapies for the treatment of critical limb ischemia.

*IP Issue Date
Mar 14, 2017
*Principal Investigation

Name: Karen Christman

Department:


Name: Jessica DeQuach

Department:

申請號碼
9592256
其他

Related Materials

DeQuach JA, Mezzano V, Miglani A, Lange S, Keller GM, Sheikh F, Christman KL. Simple and high yielding method for preparing tissue specific extracellular matrix coatings for cell culture. PLoS One. 2010 Sep 27;5(9):e13039.
Singelyn JM, DeQuach JA, Christman KL. Injectable myocardial matrix as a scaffold for myocardial tissue engineering. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:2406-8
Singelyn JM, DeQuach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ, Christman KL. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials. 2009 Oct;30(29):5409-16
Singelyn JM, Sundaramurthy P, Johnson TD, Schup-Magoffin PJ, Hu DP, Faulk DM, Wang J, Mayle KM, Bartels K, Salvatore M, Kinsey AM, Demaria AN, Dib N, Christman KL. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol. 2012 Feb 21;59(8):751-63.
Young DA, DeQuach JA, Christman KL. Human cardiomyogenesis and the need for systems biology analysis. Wiley Interdiscip Rev Syst Biol Med. 2011 Nov-Dec;3(6):666-80.
Hydrogel helps hearts heal after myocardial infarction in animals, taking step toward trials in human heart-attack patients. San Diego Biotechnology Connection News Release (Rex Graham)


Tech ID/UC Case

22431/2012-053-0


Related Cases

2012-053-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備